<DOC>
	<DOCNO>NCT00565331</DOCNO>
	<brief_summary>Our standard immunosuppressive treatment renal transplantation combination tacrolimus , mycophenolate mofetil , prednisolone . With regimen incidence acute rejection within first six month transplantation drop 20 % . The main challenge present remain improve long-term outcome prevent chronic allograft nephropathy ( CAN ) . Since acute rejection strong predictor CAN , decrease incidence acute rejection improve long-term graft survival . Current strategy prevent rejection mainly direct alloreactive T cell . Recently , attention role antibody pathogenesis acute rejection increase . In addition , anti-B cell therapy show effective disease consider mainly T cell driven , like rheumatoid arthritis . In latter case suggest anti-B cell antibody may impair antigen present function B cell . We therefore decide investigate effectiveness safety anti-B cell monoclonal antibody rituximab prophylaxis acute rejection renal transplantation . Study design : Double-blind , placebo control intervention study . One group receive single dose rituximab 375 mg/m2 intravenously time transplantation , group receive placebo infusion . Primary Objective : To determine incidence severity biopsy-confirmed acute rejection within first six month transplantation . Secondary Outcomes : - Renal function estimate endogenous creatinine clearance 6 month - Occurrence chronic allograft nephropathy 6 month - Cumulative incidence infection malignancies 6 month - Medical cost first 6 month transplantation - Patient graft survival</brief_summary>
	<brief_title>Rituximab Prevention Rejection After Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Rituximab</mesh_term>
	<criteria>Renal transplant recipient Signed , date , witnessed IRB approve informed consent Pregnancy Living donor , HLA identical . Hemolytic uremic syndrome original kidney disease . Focal segmental glomerulosclerosis recur previous graft . More two previously fail graft and/or PRA &gt; 85 % . Previous treatment antiCD20 antibody . Diabetes mellitus currently treat insulin . Total white blood cell count &lt; 3,000/mm3 platelet count &lt; 75,000/mm3 . Active infection hepatitis B , hepatitis C , HIV . History tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>